Waiting sucks for sure. Everyone wishes the process moved faster. 
 
If you want to believe and are looking for confirmation from the tech, team and new leadership then start with putting the past is in rear-view mirror. Nothing can be done about it.

1. Acknowledge that deals and progress have been made. Turn your eyes forward, appreciate that it took time to clean up the past, put a successful plan in place and execute.
 
2. Next look for confirmation that the plan is being successfully executed, as stated in the MD&A, the release of positive pre-clinical data.

3.With pre-clinical data, BTI is well positioned to negotiate licences/partnerships that reflect the value of the technology. 

4. Watch the Deals bring in non-dilutive funding to further advance programs and shareholder value.

 SEDAR MD&A
 “We believe that our licensing business model has the potential to generate considerable value for shareholders as licensed programs progress through development milestones. We will report material milestones as appropriate. Outlook Following a positive response by the FDA to the Company’s preIND submission, the Company continues to pursue multiple new sources of capital financing, as well as licensing and partnership agreements”
 The Company is currently pursuing further work on these pre clinical Pipeline Programs, including xB3004 (pain, CNS inflammation and neurodegeneration), xB3007 (Gaucher’s disease, Parkinson’s disease and Lewy Body Dementia) and xB3Progranulin for the treatment of Fronto Temporal Lobe Dementia, ALS and neuronal ceroid lipofusinosis, with the intention of strengthening our platform, creating greater value for our intellectual property and building stronger licensing partnerships. We anticipate multiple, value accretive milestones from each of these programs in 2021 to drive shareholder value. Bioasis Technologies Inc. Management’s Discussion and Analysis 15 We further anticipate that there will be additional recognition of the strength of the Company’s intellectual property portfolio as the Company executes its strategy. The Company continues to pursue and progress strategic partnering discussions for the xB3 platform. Building on our partnership with Chiesi Group in 2020, we anticipate that additional partnerships may be transacted in 2021, with funds from upfront payments being invested in the pipeline.